IL-6 is produced by adipose-derived stromal cells and promotes osteogenesis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 12, 2013, Pages 2608-2616

  Huh, Jeong Eun ^a   Lee, Soo Young ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Adipose derived stromal cell; IL 6; Osteogenesis; Osterix; STAT3; TLR

Indexed keywords

ALIZARIN RED S; ALKALINE PHOSPHATASE; CYTOKINE; DEXAMETHASONE; FLAGELLIN; INDOMETACIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LUCIFERASE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEINASE INHIBITOR; RESIQUIMOD; RETROVIRUS VECTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; TETRAMETHYLBENZIDINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 5;

ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84881084886     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.06.025     Document Type: Article

References (57)

1. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
2. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
3. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
4. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., Eng J.K., Akira S., Underhill D.M., Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
5. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
6. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3:499.
7. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
8. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
9. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
10. Hwa Cho H., Bae Y.C., Jung J.S. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 2006, 24:2744-2752.
11. Tomchuck S.L., Zwezdaryk K.J., Coffelt S.B., Waterman R.S., Danka E.S., Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008, 26:99-107.
12. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., Cohen I.R., Zipori D. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007, 109:1422-1432.
13. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
14. Sehgal P.B., Helfgott D.C., Santhanam U., Tatter S.B., Clarick R.H., Ghrayeb J., May L.T. Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts. J. Exp. Med. 1988, 167:1951-1956.
15. Jirik F.R., Podor T.J., Hirano T., Kishimoto T., Loskutoff D.J., Carson D.A., Lotz M. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J. Immunol. 1989, 142:144-147.
16. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
17. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 2012, 8:1237-1247.
18. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993, 260:1808-1810.
19. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
20. Horvath C.M., Wen Z., Darnell J.E. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995, 9:984-994.
21. Nombela-Arrieta C., Ritz J., Silberstein L.E. The elusive nature and function of mesenchymal stem cells. Nat. Rev. Mol. Cell Biol. 2011, 12:126-131.
22. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
23. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
24. Shi M., Liu Z.W., Wang F.S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin. Exp. Immunol. 2011, 164:1-8.
25. Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20:419-427.
26. Bunnell B.A., Flaat M., Gagliardi C., Patel B., Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008, 45:115-120.
27. Huh J.E., Ko R., Jung H.J., Lee S.Y. Glycogen synthase kinase 3beta promotes osteogenic differentiation of murine adipose-derived stromal cells. PLoS One 2013, 8:e54551.
28. Kim H., Choi H.K., Shin J.H., Kim K.H., Huh J.Y., Lee S.A., Ko C.Y., Kim H.S., Shin H.I., Lee H.J., Jeong D., Kim N., Choi Y., Lee S.Y. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J. Clin. Invest. 2009, 119:813-825.
29. Xing W., Singgih A., Kapoor A., Alarcon C.M., Baylink D.J., Mohan S. Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. J. Biol. Chem. 2007, 282:22052-22061.
30. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
31. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
32. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
33. Zuk P.A., Zhu M., Ashjian P., De Ugarte D.A., Huang J.I., Mizuno H., Alfonso Z.C., Fraser J.K., Benhaim P., Hedrick M.H. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 2002, 13:4279-4295.
34. Gimble J.M., Katz A.J., Bunnell B.A. Adipose-derived stem cells for regenerative medicine. Circ. Res. 2007, 100:1249-1260.
35. Strem B.M., Hicok K.C., Zhu M., Wulur I., Alfonso Z., Schreiber R.E., Fraser J.K., Hedrick M.H. Multipotential differentiation of adipose tissue-derived stem cells. Keio J. Med. 2005, 54:132-141.
36. Schaffler A., Buchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007, 25:818-827.
37. Cawthorn W.P., Scheller E.L., MacDougald O.A. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J. Lipid Res. 2012, 53:227-246.
38. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
39. Hou B., Reizis B., DeFranco A.L. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 2008, 29:272-282.
40. Nagai Y., Garrett K.P., Ohta S., Bahrun U., Kouro T., Akira S., Takatsu K., Kincade P.W. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006, 24:801-812.
41. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
42. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
43. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
44. Schaffler A., Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol. 2010, 31:228-235.
45. Hopkins P.A., Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin. Exp. Immunol. 2005, 140:395-407.
46. Jones S.A. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 2005, 175:3463-3468.
47. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 2000, 1:510-514.
48. Diehl S., Chow C.W., Weiss L., Palmetshofer A., Twardzik T., Rounds L., Serfling E., Davis R.J., Anguita J., Rincon M. Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. J. Exp. Med. 2002, 196:39-49.
49. Erices A., Conget P., Rojas C., Minguell J.J. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp. Cell Res. 2002, 280:24-32.
50. Nishimura R., Moriyama K., Yasukawa K., Mundy G.R., Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner. Res. 1998, 13:777-785.
51. Scambia G., Testa U., Panici P.B., Martucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer 1994, 57:318-323.
52. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 1989, 170:1409-1414.
53. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 1992, 148:2175-2180.
54. Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int. J. Med. Sci. 2012, 9:825-832.
55. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G.A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994, 13:1189-1196.
56. Hushaw L.L., Sawaqed R., Sweis G., Reigle J., Gopal A., Brandt D., Sweis N., Curran J., Niewold T.B., Sweiss N.J. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther. Clin. Risk Manag. 2010, 6:143-152.
57. Keyser K.A., Beagles K.E., Kiem H.P. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 2007, 16:555-562.